146 related articles for article (PubMed ID: 35776258)
21. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.
Wu G; Huang S; Nastiuk KL; Li J; Gu J; Wu M; Zhang Q; Lin H; Wu D
Prostate; 2015 May; 75(7):777-782. PubMed ID: 25731771
[TBL] [Abstract][Full Text] [Related]
22. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
[TBL] [Abstract][Full Text] [Related]
23. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.
Agarwal N; Hahn AW; Gill DM; Farnham JM; Poole AI; Cannon-Albright L
JAMA Oncol; 2017 Jun; 3(6):856-857. PubMed ID: 28208175
[TBL] [Abstract][Full Text] [Related]
24. Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Gingras S; Moriggl R; Groner B; Simard J
Mol Endocrinol; 1999 Jan; 13(1):66-81. PubMed ID: 9892013
[TBL] [Abstract][Full Text] [Related]
25. Inheritance of a common androgen synthesis variant allele is associated with female COVID susceptibility in UK Biobank.
McManus JM; Sabharwal N; Bazeley P; Sharifi N
Eur J Endocrinol; 2022 May; 187(1):1-14. PubMed ID: 35521709
[TBL] [Abstract][Full Text] [Related]
26. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
27. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.
Han FF; Ren LL; Xuan LL; Lv YL; Liu H; Gong LL; An ZL; Liu LH
Cancer Chemother Pharmacol; 2021 Jan; 87(1):103-112. PubMed ID: 33141329
[TBL] [Abstract][Full Text] [Related]
28. Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics.
Naelitz BD; Sharifi N
Trends Endocrinol Metab; 2020 Sep; 31(9):680-690. PubMed ID: 32565196
[TBL] [Abstract][Full Text] [Related]
29. Expression and gene variation studies deny association of human HSD3B1 gene with aldosterone production or blood pressure.
Verwoert GC; Hofland J; Amin N; Mattace-Raso FU; Sijbrands EJ; Hofman A; van den Meiracker AH; Uitterlinden AG; van Duijn CM; de Jong FH; Danser AH
Am J Hypertens; 2015 Jan; 28(1):113-20. PubMed ID: 24951726
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.
Shiota M; Fujimoto N; Sekino Y; Tsukahara S; Nagakawa S; Takamatsu D; Abe T; Kinoshita F; Ueda S; Ushijima M; Matsumoto T; Kashiwagi E; Inokuchi J; Uchiumi T; Oda Y; Eto M
Andrologia; 2022 Feb; 54(1):e14307. PubMed ID: 34747051
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
Chang YC; Lin CH; Lin JC; Cheng SP; Chen SN; Liu CL
J Surg Res; 2019 Sep; 241():8-14. PubMed ID: 31004874
[TBL] [Abstract][Full Text] [Related]
32. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
33. HSD3B1 genotype predicts castration resistance.
Thoma C
Nat Rev Urol; 2020 Apr; 17(4):193. PubMed ID: 32112052
[No Abstract] [Full Text] [Related]
34. Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy.
Shimodaira M; Nakayama T; Sato I; Sato N; Izawa N; Mizutani Y; Furuya K; Yamamoto T
Endocrine; 2012 Dec; 42(3):700-7. PubMed ID: 22638611
[TBL] [Abstract][Full Text] [Related]
35. Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk.
Amrousy YM; Haffez H; Abdou DM; Atya HB
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35795973
[TBL] [Abstract][Full Text] [Related]
36. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
37. Genetic variation in the HSD3B1 gene and recurrent spontaneous abortions.
Ntostis P; Peraki O; Boulgari A; Agiannitopoulos K; Pantos K; Lamnissou K
J Matern Fetal Neonatal Med; 2012 Apr; 25(4):408-10. PubMed ID: 21631238
[TBL] [Abstract][Full Text] [Related]
38. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; Hackl W; Thuerlimann B; Viale G; Di Leo A; Colleoni M; Regan MM; Loi S
Ann Oncol; 2020 Oct; 31(10):1359-1365. PubMed ID: 32652112
[TBL] [Abstract][Full Text] [Related]
39. HSD3B1 gene polymorphism and female pattern hair loss in women with polycystic ovary syndrome.
Tu YA; Lin SJ; Chen PL; Chou CH; Huang CC; Ho HN; Chen MJ
J Formos Med Assoc; 2019 Aug; 118(8):1225-1231. PubMed ID: 31056381
[TBL] [Abstract][Full Text] [Related]
40. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
